385 related articles for article (PubMed ID: 31028033)
1. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
[TBL] [Abstract][Full Text] [Related]
2. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer.
Stromnes IM; Hulbert A; Rollins MR; Basom RS; Delrow J; Bonson P; Burrack AL; Hingorani SR; Greenberg PD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210305
[TBL] [Abstract][Full Text] [Related]
3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
4. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
[TBL] [Abstract][Full Text] [Related]
5. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Schmitt TM; Hulbert A; Brockenbrough JS; Nguyen H; Cuevas C; Dotson AM; Tan X; Hotes JL; Greenberg PD; Hingorani SR
Cancer Cell; 2015 Nov; 28(5):638-652. PubMed ID: 26525103
[TBL] [Abstract][Full Text] [Related]
6. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
[TBL] [Abstract][Full Text] [Related]
7. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
8. Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.
Hundeyin M; Kurz E; Mishra A; Rossi JAK; Liudahl SM; Leis KR; Mehrotra H; Kim M; Torres LE; Ogunsakin A; Link J; Sears RC; Sivagnanam S; Goecks J; Islam KMS; Dolgalev I; Savadkar S; Wang W; Aykut B; Leinwand J; Diskin B; Adam S; Israr M; Gelas M; Lish J; Chin K; Farooq MS; Wadowski B; Wu J; Shah S; Adeegbe DO; Pushalkar S; Vasudevaraja V; Saxena D; Wong KK; Coussens LM; Miller G
Cancer Discov; 2019 Sep; 9(9):1288-1305. PubMed ID: 31266770
[TBL] [Abstract][Full Text] [Related]
9. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
10. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract][Full Text] [Related]
11. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
12. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
Chao T; Furth EE; Vonderheide RH
Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
[TBL] [Abstract][Full Text] [Related]
13. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.
Stromnes IM; Brockenbrough JS; Izeradjene K; Carlson MA; Cuevas C; Simmons RM; Greenberg PD; Hingorani SR
Gut; 2014 Nov; 63(11):1769-81. PubMed ID: 24555999
[TBL] [Abstract][Full Text] [Related]
14. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
17. CSF1R
Candido JB; Morton JP; Bailey P; Campbell AD; Karim SA; Jamieson T; Lapienyte L; Gopinathan A; Clark W; McGhee EJ; Wang J; Escorcio-Correia M; Zollinger R; Roshani R; Drew L; Rishi L; Arkell R; Evans TRJ; Nixon C; Jodrell DI; Wilkinson RW; Biankin AV; Barry ST; Balkwill FR; Sansom OJ
Cell Rep; 2018 May; 23(5):1448-1460. PubMed ID: 29719257
[TBL] [Abstract][Full Text] [Related]
18. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT
Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20212-7. PubMed ID: 24277834
[TBL] [Abstract][Full Text] [Related]
19. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model.
Burrack AL; Rollins MR; Spartz EJ; Mesojednik TD; Schmiechen ZC; Raynor JF; Wang IX; Kedl RM; Stromnes IM
J Immunol; 2021 Mar; 206(6):1372-1384. PubMed ID: 33558374
[TBL] [Abstract][Full Text] [Related]
20. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
